F S&P 500
5,294.50 -30.25 (-0.57%) F Dow Jones
38,724.00 -220.00 (-0.56%) F Nasdaq
18,828.75 -111.75 (-0.59%) E-mini Russell 2000 Index Futur
2,052.20 -21.00 (-1.01%) Petróleo
80.52 +0.69 (+0.86%) Oro
2,344.70 -11.80 (-0.50%)
Theraclion SA (TCLIF)
Theraclion SA
244, avenue Pierre Brossolette
Malakoff 92240
France
33 1 55 48 90 70
https://www.theraclion.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Yann M. Duchesne | Executive Chairman | 512.65k | N/D | 1956 |
| Mr. Martin Deterre | Chief Executive Officer | N/D | N/D | N/D |
| Ms. Laurence Gericot | Administrative & Financial Director | N/D | N/D | 1965 |
| Gaylord Tallec | Vice President of Operations | N/D | N/D | N/D |
| Jérémie Anquez | VP Research & Chief Scientific Officer | N/D | N/D | N/D |
| Mr. Jose Abellan-Martinez | Vice President of Sales & Business Development | N/D | N/D | N/D |
| Marie Berne | Marketing & Customer Relations Director | N/D | N/D | N/D |
| Mr. Michel Nuta M.D. | VP of Veins & Chief Medical Officer | N/D | N/D | N/D |
Descripción
Theraclion SA designs and markets high-tech therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. Theraclion SA was incorporated in 2004 and is based in Malakoff, France.
Gestión corporativa
La calificación ISS Governance QuickScore de Theraclion SA a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
